SCHEDULE: Vivo Funds Disclose 7.4% Stake in Camp4 Therapeutics

Vivo Opportunity Fund Holdings, L.P. and its affiliates have disclosed a combined beneficial ownership of 7.4% in Camp4 Therapeutics Corp, as reported in a Schedule 13G filing.

Summary

• Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, beneficially own 3,856,991 shares of Camp4 Therapeutics Corp common stock.
• This ownership represents 7.4% of the total outstanding common stock.
• Additionally, Vivo Opportunity Cayman Fund, L.P. and its general partner, Vivo Opportunity Cayman, LLC, beneficially own 389,577 shares, representing 0.8% of the class.
• The total outstanding shares of Camp4 Therapeutics Corp were 51,880,185 as of December 18, 2025.
• The shares were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant stake by an institutional investor like Vivo Funds can indicate confidence in Camp4 Therapeutics Corp's potential, even though the filing itself is purely a disclosure of ownership.

Positives

• A significant stake by institutional investors like Vivo Funds can signal confidence in the company's long-term prospects.
• The disclosure of a 7.4% stake by Vivo Opportunity Fund Holdings, L.P. and its general partner indicates a substantial investment.

Negatives

• The filing itself does not contain negative information; it is a disclosure of ownership.

Risks

• The filing does not explicitly mention risks related to Camp4 Therapeutics Corp; it is a beneficial ownership report.

Future Outlook

This filing does not provide forward-looking statements or guidance from Camp4 Therapeutics Corp.

Industry Context

StockSavvy.ai notes that the disclosure of a significant stake by a venture capital firm like Vivo Funds in a biotechnology company such as Camp4 Therapeutics Corp is a common occurrence, often following private funding rounds or public offerings. This type of investment signals continued interest from specialized life sciences investors in the biotech sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor could be viewed positively, potentially increasing investor confidence and liquidity.
• Company Management: A large institutional holder may exert influence on strategic decisions, though the filing states the shares were not acquired for control purposes.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses a significant beneficial ownership stake by Vivo Funds in Camp4 Therapeutics Corp. While the presence of a substantial institutional investor can be a positive indicator of confidence, the filing itself does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further financial or clinical updates from Camp4 Therapeutics Corp to make a more informed decision, using this ownership disclosure as one piece of the broader investment mosaic.

Keywords

Camp4 Therapeutics, Vivo Opportunity Fund, Vivo Opportunity, LLC, Vivo Opportunity Cayman Fund, Vivo Opportunity Cayman, LLC, beneficial ownership, Schedule 13G, common stock, institutional investment, biotech, pharmaceutical